CN113164782A - 治疗滤泡型淋巴瘤的方法 - Google Patents

治疗滤泡型淋巴瘤的方法 Download PDF

Info

Publication number
CN113164782A
CN113164782A CN201980078851.9A CN201980078851A CN113164782A CN 113164782 A CN113164782 A CN 113164782A CN 201980078851 A CN201980078851 A CN 201980078851A CN 113164782 A CN113164782 A CN 113164782A
Authority
CN
China
Prior art keywords
subject
ibrutinib
mutations
genes
atp6ap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980078851.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴拉苏布拉曼尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN113164782A publication Critical patent/CN113164782A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980078851.9A 2018-11-30 2019-11-26 治疗滤泡型淋巴瘤的方法 Pending CN113164782A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
US62/773678 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
CN113164782A true CN113164782A (zh) 2021-07-23

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980078851.9A Pending CN113164782A (zh) 2018-11-30 2019-11-26 治疗滤泡型淋巴瘤的方法

Country Status (16)

Country Link
US (1) US20200171034A1 (https=)
EP (1) EP3886992A1 (https=)
JP (1) JP2022513666A (https=)
KR (1) KR20210097160A (https=)
CN (1) CN113164782A (https=)
AU (1) AU2019388899A1 (https=)
BR (1) BR112021009978A2 (https=)
CA (1) CA3120960A1 (https=)
EA (1) EA202191509A1 (https=)
IL (1) IL283365A (https=)
JO (1) JOP20210126A1 (https=)
MA (1) MA54292A (https=)
MX (1) MX2021006368A (https=)
PH (1) PH12021551140A1 (https=)
SG (1) SG11202105309YA (https=)
WO (1) WO2020112761A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263496A (zh) * 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
WO2016149542A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
CN107530293A (zh) * 2015-04-06 2018-01-02 詹森药业有限公司 包含依鲁替尼的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914284A1 (en) * 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PH12021551936A1 (en) * 2019-02-15 2022-05-23 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263496A (zh) * 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
WO2016149542A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
CN107530293A (zh) * 2015-04-06 2018-01-02 詹森药业有限公司 包含依鲁替尼的组合物
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor

Also Published As

Publication number Publication date
JOP20210126A1 (ar) 2019-11-26
SG11202105309YA (en) 2021-06-29
KR20210097160A (ko) 2021-08-06
EP3886992A1 (en) 2021-10-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (ja) 2022-02-09
EA202191509A1 (ru) 2021-10-26
BR112021009978A2 (pt) 2021-08-17
WO2020112761A1 (en) 2020-06-04
MA54292A (fr) 2021-10-06
PH12021551140A1 (en) 2021-10-25
AU2019388899A1 (en) 2021-06-10
IL283365A (en) 2021-07-29
MX2021006368A (es) 2021-10-13
CA3120960A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
KR102622309B1 (ko) 염색체 상호작용의 검출
EP4161658A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
EP4222286B1 (en) Outcome prediction of bladder or kidney cancer
Kalogeropoulos et al. Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue
Leprieur et al. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
WO2021175746A1 (en) Prediction of radiotherapy response for prostate cancer subject based on immune defense response genes
CN113287016A (zh) 作为对肾细胞癌抗pd1/pd-l1/pd-l2抗体的反应性的标志物的微生物同群合物
Ennishi The biology of the tumor microenvironment in DLBCL: Targeting the “don’t eat me” signal
CN111187835A (zh) 胰腺癌的靶点erbb2及其在诊断和治疗中的应用
Mo et al. A six-gene prognostic model based on neutrophil extracellular traps (NETs)-related gene signature for lung adenocarcinoma
Sivanand et al. The neoantigen landscape of mycosis fungoides
CN113164782A (zh) 治疗滤泡型淋巴瘤的方法
WO2022159720A2 (en) Methods to quantify rate of clonal expansion and methods for treating clonal hematopoiesis and hematologic malignancies
Lau et al. Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity via spatial transcriptomic analysis of two cancer patients with COVID-19 co-morbidity
JP2023538783A (ja) 前立腺がんの放射線治療用線量の選択
De Marchi et al. EP1. 04-11 Frequency of Microsatellite Instability (MSI) in Brazilian TKI non-treatable Non-Small Cell Lung Cancer (NSCLC) patients
EP2320932B1 (en) Methods of predicting cancer lethality using replikin counts
CN117925821A (zh) 一种致死性电离辐射损伤标志物及其应用
Perco et al. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40‐CD40L costimulation blockade
Shatara et al. ATRT-21. Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach in three children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoid tumor
US20250019766A1 (en) Tumor cell identification by mapping mutations in bulk dna sequences to single cell rna sequences
EP4722388A1 (en) Prediction of an outcome of a subject suffering from acute myoloid leukemia
Shboul et al. FISH-based investigation of CDKN2A and IFNA14 in glioblastoma
CN113528656B (zh) 评价胶质瘤和/或胃腺癌预后性的试剂盒和系统
Gonzalez-Vicente et al. Analysis of Glomerular Transcriptomes from Nephrotic Patients Suggest APOL1 Risk Variants Impact Parietal Epithelial Cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723

WD01 Invention patent application deemed withdrawn after publication